Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 7/20 | 0.46 |
| ▸ | TNKS | O95271 | 2/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12846181 | 0.80 | ALDH1A1 (0.52) | KDM4EPARP1 | |
| SCHEMBL3087666 | 0.77 | KDM4E (0.70) | KDM4EPKMGPR119TGFBR1BRD4 | |
| SCHEMBL4514765 | 0.77 | KDM4E (0.53) | KDM4EPKMBCDIN3DIDO1TDO2 | |
| SCHEMBL1316679 | 0.75 | MAPK8 (0.52) | KDM4EPKMGPR119TGFBR1PRMT5 | |
| SCHEMBL13793840 | 0.75 | KDM4E (0.58) | KDM4EPKMBCDIN3DGPR119TGFBR1 | |
| SCHEMBL3035919 | 0.75 | GRIN2B (0.68) | KDM4EPKMGPR119TGFBR1PRMT5 | |
| SCHEMBL12846290 | 0.74 | PDGFRB (0.47) | BRD4 | |
| SCHEMBL24380660 | 0.74 | KDM4E (0.54) | KDM4EPKMBCDIN3DIDO1GPR119 | |
| SCHEMBL24000701 | 0.74 | ENPP1 (0.59) | KDM4EPKM | |
| SCHEMBL22716661 | 0.73 | KDM4E (0.61) | KDM4EPKMBCDIN3DIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072972-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-12 | — | — | US | disclosed |
| US-8946221-B2 | Phthalazine derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2015-02-03 | — | — | US | disclosed |
| US-20110065684-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | MEVELLEC LAURENCE ANNE | 2011-03-17 | — | — | US | disclosed |
| US-7803795-B2 | Phthalazine derivatives as parp inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-28 | — | — | US | disclosed |
| US-7803795-B2 | Phthalazine derivatives as parp inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-28 | — | — | US | disclosed |
| US-20080139568-A1 | Phthalazine Derivatives as Parp Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139568-A1 | Phthalazine Derivatives as Parp Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072972-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | KDM4E 468/4885PKM 776/4885BCDIN3D 2823/4885 |
| US-20080139568-A1 | Phthalazine Derivatives as Parp Inhibitors | PARP1, PARP2, PARP11 | KDM4E 476/4885PKM 813/4885BCDIN3D 2896/4885 |
| US-20110065684-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | KDM4E 468/4885PKM 776/4885BCDIN3D 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.